Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Randomized trial of acute changes in plasma phosphate after phosphorus-standardized meals in peritoneal dialysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  4. Impact of CKD on Household Income

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • FIDELIO-DKD Investigators
Vis graf over relationer

Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2 diabetes (T2D). This analysis explores the impact of use of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) on the treatment effect of finerenone.

Methods: Patients (N = 5674) with T2D, urine albumin-to-creatinine ratio (UACR) of 30 to 5000 mg/g and estimated glomerular filtration rate (eGFR) of 25 to <75 ml/min per 1.73 m2 receiving optimized renin-angiotensin system (RAS) blockade were randomized to finerenone or placebo. Endpoints were change in UACR and a composite kidney outcome (time to kidney failure, sustained decrease in eGFR ≥40% from baseline, or renal death) and key secondary cardiovascular outcomes (time to cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) (ClinicalTrials.gov, NCT02540993).

Results: Of 5674 patients, 259 (4.6%) received an SGLT-2i at baseline. Reduction in UACR with finerenone was found with or without use of SGLT-2i at baseline, with ratio of least-squares means of 0.69 (95% CI = 0.66-0.71) and 0.75 (95% CI -= 0.62-0.90), respectively (P interaction = 0.31). Finerenone also significantly reduced the kidney and key secondary cardiovascular outcomes versus placebo; there was no clear difference in the results by SGLT-2i use at baseline (P interaction = 0.21 and 0.46, respectively) or at any time during the trial. Safety was balanced with or without SGLT-2i use at baseline, with fewer hyperkalemia events with finerenone in the SGLT-2i group (8.1% vs. 18.7% without).

Conclusion: UACR improvement was observed with finerenone in patients with CKD and T2D already receiving SGLT-2is at baseline, and benefits on kidney and cardiovascular outcomes appear consistent irrespective of use of SGLT-2i.

OriginalsprogEngelsk
TidsskriftKidney International Reports
Vol/bind7
Udgave nummer1
Sider (fra-til)36-45
ISSN2468-0249
DOI
StatusUdgivet - jan. 2022

Bibliografisk note

Publisher Copyright:
© 2021 International Society of Nephrology

ID: 69771914